Lupin is currently trading at Rs. 898.90, up by 0.80 points or 0.09% from its previous closing of Rs. 898.10 on the BSE.
The scrip opened at Rs. 901.00 and has touched a high and low of Rs. 907.55 and Rs. 893.80 respectively. So far 48687 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 30-Oct-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 917.75 and Rs. 874.00 respectively. The current market cap of the company is Rs. 40625.08 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.89% and 15.10% respectively.
Lupin and Eli Lilly and Company (India) (Lilly India) have expanded their business partnership aimed at widening access to innovative diabetes medicines in India. Under the new partnership, Lupin will distribute and market Lilly’s Aplevant (dulaglutide), a once-weekly injection for type 2 diabetes treatment.
Aplevant (dulaglutide) is a once-weekly injectable solution for adults with type 2 diabetes mellitus. Lupin expects to make Aplevant available in India in October 2018.
This announcement builds on the Lupin and Lilly India business partnership initiated in 2011 to expand the promotion and distribution of Lilly’s diabetes portfolio in India where Lupin has a large network.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
